Sherlock Biosciences acquires Sense Biodetection to enhance molecular diagnostics

Wednesday 1st February, 2023

Sherlock Biosciences (Sherlock) is shaping the future of molecular diagnostics. Its acquisition of Sense Biodetection (Sense), a global molecular diagnostics innovator, will empower it to create a faster path to commercialising its technology. Marriott Harrison acted as UK legal counsel to Sherlock.

The deal will enable Sherlock to bring highly accurate, advanced handheld tests to global consumers for a wide range of diseases. Sense’s Veros™ instrument-free rapid molecular test platform, coupled with Sherlock’s proprietary engineering biology tools, is a powerful combination which will allow the companies to realise their collective vision of democratising and decentralising diagnostics.

Founded in 2019, Sherlock develops disruptive products that will empower people to access answers and have more control over their health decisions. Through its engineering biology tools, it is bringing together the accuracy of PCR with the convenience and simplicity of antigen tests for molecular diagnostics at the point-of-need. The company is backed by leading investors in the life-sciences sector.

Sense brings lab-quality results through easy-to-use, rapid, disposable molecular tests without the constraints of an instrument. In doing so, it empowers patients and improves access to healthcare. With locations in Boston, Oxford and Cambridge, Sense brings a wealth of global industry knowledge to its offering.

David Strong led a multidisciplinary team from Marriott Harrison advising Sherlock, which included Bradley Heath and Ben Cole. Marriott Harrison is pleased to have worked with Sherlock on its acquisition, furthering the firm’s credentials of working with future-shaping companies in the life sciences sector.

#acquisition #biotech #lifesciences

Articles by Bradley Heath